Cerus Q2 revenue beats estimates, raises 2025 guidance

Overview

• Cerus Q2 total revenue rises 19% yr/yr to $60.1 mln, beating estimates, per LSEG data

• Q2 product revenue up 16% yr/yr to $52.4 mln, driven by IFC and platelet sales

• Co raises full-year 2025 product revenue guidance to $200 mln - $203 mln

Outlook

• Cerus raises full-year 2025 product revenue guidance to $200 mln-$203 mln

• Company increases 2025 IFC revenue guidance to $16 mln-$18 mln

• Cerus expects positive full-year 2025 non-GAAP adjusted EBITDA

• Company anticipates continued growth in second half of 2025

Result Drivers

• IFC DEMAND - Strong demand for INTERCEPT Fibrinogen Complex drove product revenue growth, with Q2 revenue rising to $5.6 mln from $2.0 mln year-ago

• INT200 DEVICE - Successful launch and adoption of the new LED-based INT200 illumination device exceeded performance expectations, per CEO

• GOVERNMENT CONTRACTS - Increase in government contract revenue was driven by R&D activities for the INTERCEPT RBC program and next-gen pathogen reduction technology

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Cerus Corp is $5.00, about 74% above its August 4 closing price of $1.30

Press Release: ID:nBw4Q9ct8a